Crinetics Net Receivables vs Total Liab Analysis

CRNX Stock

USD 46.86 0.61 1.29%

Crinetics Pharmaceuticals financial indicator trend analysis is way more than just evaluating Crinetics Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Crinetics Pharmaceuticals is a good investment. Please check the relationship between Crinetics Pharmaceuticals Net Receivables and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Crinetics Pharmaceuticals Net Receivables account and Total Liab. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Crinetics Pharmaceuticals' Net Receivables and Total Liab is 0.95. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Liab in the same time period over historical financial statements of Crinetics Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Crinetics Pharmaceuticals' Net Receivables and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Crinetics Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Receivables i.e., Crinetics Pharmaceuticals' Net Receivables and Total Liab go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Receivables

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Crinetics Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Crinetics Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.Selling General Administrative is likely to rise to about 61 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 188.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	157K	4.3M	13.4M	14.1M
Net Interest Income	157K	4.3M	13.4M	14.1M

Interest Income Net Interest Income

Crinetics Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.87	0.97	0.99	0.5	0.88	0.95	0.9	-0.17	-0.98	0.77	0.52	0.91	0.91	0.17	-0.81	1.0	0.95	0.88	0.84	-0.81	0.56	0.83	0.88	0.66	-0.92
Short Long Term Debt Total	0.87		0.92	0.89	0.85	0.81	0.69	1.0	0.2	-0.85	0.43	0.2	1.0	0.98	-0.16	-0.94	0.85	0.98	0.64	0.59	-0.94	0.85	0.58	0.7	0.43	-0.63
Other Current Liab	0.97	0.92		0.99	0.6	0.95	0.88	0.94	0.06	-0.98	0.63	0.31	0.94	0.92	0.09	-0.86	0.96	0.97	0.8	0.8	-0.86	0.68	0.73	0.86	0.65	-0.85
Total Current Liabilities	0.99	0.89	0.99		0.53	0.92	0.92	0.91	-0.03	-0.99	0.72	0.39	0.92	0.89	0.16	-0.83	0.98	0.96	0.86	0.85	-0.83	0.62	0.79	0.88	0.7	-0.9
Total Stockholder Equity	0.5	0.85	0.6	0.53		0.5	0.24	0.83	0.48	-0.47	-0.06	-0.14	0.81	0.81	-0.53	-0.83	0.47	0.73	0.19	0.14	-0.83	0.91	0.14	0.34	0.0	-0.13
Other Liab	0.88	0.81	0.95	0.92	0.5		0.8	0.82	0.21	-0.89	0.5	0.11	0.83	0.8	0.11	-0.76	0.87	0.87	0.66	0.73	-0.76	0.6	0.68	0.78	0.64	-0.79
Net Tangible Assets	0.95	0.69	0.88	0.92	0.24	0.8		0.73	-0.39	-0.93	0.89	0.67	0.74	0.76	0.36	-0.63	0.97	0.82	0.93	0.88	-0.63	0.29	0.92	0.85	0.72	-0.98
Property Plant And Equipment Net	0.9	1.0	0.94	0.91	0.83	0.82	0.73		0.17	-0.88	0.47	0.22	1.0	0.98	-0.13	-0.94	0.88	0.99	0.68	0.63	-0.94	0.83	0.61	0.73	0.48	-0.66
Net Debt	-0.17	0.2	0.06	-0.03	0.48	0.21	-0.39	0.17		0.09	-0.6	-0.92	0.16	0.05	-0.42	-0.23	-0.2	0.07	-0.4	-0.27	-0.23	0.51	-0.41	-0.2	-0.1	0.38
Retained Earnings	-0.98	-0.85	-0.98	-0.99	-0.47	-0.89	-0.93	-0.88	0.09		-0.76	-0.43	-0.89	-0.86	-0.2	0.78	-0.98	-0.93	-0.89	-0.9	0.78	-0.59	-0.77	-0.9	-0.72	0.93
Accounts Payable	0.77	0.43	0.63	0.72	-0.06	0.5	0.89	0.47	-0.6	-0.76		0.77	0.49	0.48	0.55	-0.32	0.79	0.58	0.94	0.88	-0.32	0.0	0.88	0.68	0.78	-0.91
Cash	0.52	0.2	0.31	0.39	-0.14	0.11	0.67	0.22	-0.92	-0.43	0.77		0.24	0.34	0.35	-0.16	0.54	0.32	0.66	0.5	-0.16	-0.17	0.64	0.48	0.27	-0.63
Non Current Assets Total	0.91	1.0	0.94	0.92	0.81	0.83	0.74	1.0	0.16	-0.89	0.49	0.24		0.98	-0.11	-0.94	0.89	0.99	0.7	0.65	-0.94	0.82	0.62	0.74	0.49	-0.68
Non Currrent Assets Other	0.91	0.98	0.92	0.89	0.81	0.8	0.76	0.98	0.05	-0.86	0.48	0.34	0.98		-0.19	-0.92	0.89	0.97	0.65	0.6	-0.92	0.78	0.63	0.75	0.37	-0.67
Other Assets	0.17	-0.16	0.09	0.16	-0.53	0.11	0.36	-0.13	-0.42	-0.2	0.55	0.35	-0.11	-0.19		0.2	0.19	-0.01	0.51	0.42	0.2	-0.47	0.5	0.01	0.72	-0.44
Long Term Debt	-0.81	-0.94	-0.86	-0.83	-0.83	-0.76	-0.63	-0.94	-0.23	0.78	-0.32	-0.16	-0.94	-0.92	0.2		-0.79	-0.92	-0.58	-0.44	1.0	-0.84	-0.49	-0.67	-0.32	0.55
Cash And Short Term Investments	1.0	0.85	0.96	0.98	0.47	0.87	0.97	0.88	-0.2	-0.98	0.79	0.54	0.89	0.89	0.19	-0.79		0.94	0.89	0.85	-0.79	0.53	0.85	0.88	0.67	-0.93
Net Receivables	0.95	0.98	0.97	0.96	0.73	0.87	0.82	0.99	0.07	-0.93	0.58	0.32	0.99	0.97	-0.01	-0.92	0.94		0.77	0.72	-0.92	0.75	0.71	0.78	0.57	-0.77
Common Stock Total Equity	0.88	0.64	0.8	0.86	0.19	0.66	0.93	0.68	-0.4	-0.89	0.94	0.66	0.7	0.65	0.51	-0.58	0.89	0.77		0.9	-0.58	0.26	0.87	0.75	0.83	-0.94
Common Stock Shares Outstanding	0.84	0.59	0.8	0.85	0.14	0.73	0.88	0.63	-0.27	-0.9	0.88	0.5	0.65	0.6	0.42	-0.44	0.85	0.72	0.9		-0.44	0.29	0.76	0.82	0.82	-0.94
Long Term Debt Total	-0.81	-0.94	-0.86	-0.83	-0.83	-0.76	-0.63	-0.94	-0.23	0.78	-0.32	-0.16	-0.94	-0.92	0.2	1.0	-0.79	-0.92	-0.58	-0.44		-0.84	-0.49	-0.67	-0.32	0.55
Non Current Liabilities Total	0.56	0.85	0.68	0.62	0.91	0.6	0.29	0.83	0.51	-0.59	0.0	-0.17	0.82	0.78	-0.47	-0.84	0.53	0.75	0.26	0.29	-0.84		0.08	0.54	0.08	-0.26
Capital Surpluse	0.83	0.58	0.73	0.79	0.14	0.68	0.92	0.61	-0.41	-0.77	0.88	0.64	0.62	0.63	0.5	-0.49	0.85	0.71	0.87	0.76	-0.49	0.08		0.57	0.79	-0.87
Inventory	0.88	0.7	0.86	0.88	0.34	0.78	0.85	0.73	-0.2	-0.9	0.68	0.48	0.74	0.75	0.01	-0.67	0.88	0.78	0.75	0.82	-0.67	0.54	0.57		0.46	-0.87
Other Current Assets	0.66	0.43	0.65	0.7	0.0	0.64	0.72	0.48	-0.1	-0.72	0.78	0.27	0.49	0.37	0.72	-0.32	0.67	0.57	0.83	0.82	-0.32	0.08	0.79	0.46		-0.79
Other Stockholder Equity	-0.92	-0.63	-0.85	-0.9	-0.13	-0.79	-0.98	-0.66	0.38	0.93	-0.91	-0.63	-0.68	-0.67	-0.44	0.55	-0.93	-0.77	-0.94	-0.94	0.55	-0.26	-0.87	-0.87	-0.79

Click cells to compare fundamentals

Crinetics Pharmaceuticals Account Relationship Matchups

Crinetics Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	130.4M	183.4M	351.0M	352.2M	635.4M	667.1M
Other Current Liab	2.8M	4.9M	7.5M	17.5M	31.2M	32.7M
Total Current Liabilities	8.3M	10.5M	16.0M	27.7M	43.9M	46.1M
Total Stockholder Equity	(93.8M)	(167.6M)	(275.3M)	(439.2M)	539.1M	566.1M
Net Tangible Assets	117.1M	168.9M	331.9M	316.3M	363.8M	382.0M
Property Plant And Equipment Net	6.5M	5.4M	4.7M	5.0M	57.4M	60.3M
Net Debt	(35.5M)	(89.1M)	(197.6M)	(30.6M)	(3.2M)	(3.3M)
Retained Earnings	(93.8M)	(167.6M)	(275.3M)	(439.2M)	(653.7M)	(621.0M)
Accounts Payable	5.5M	5.6M	8.5M	6.9M	6.5M	4.8M
Cash	40.3M	93.1M	200.7M	32.7M	54.9M	67.8M
Non Current Assets Total	7.0M	6.0M	6.3M	7.0M	61.2M	64.3M
Non Currrent Assets Other	82K	40K	568K	37K	2.0M	2.1M
Other Assets	582K	2.8M	568K	2.0M	1.0	0.95
Cash And Short Term Investments	118.4M	170.9M	333.7M	334.4M	558.6M	586.5M
Net Receivables	1.4M	1.8M	2.0M	2.4M	9.4M	9.8M
Common Stock Shares Outstanding	24.2M	30.4M	38.4M	52.0M	58.1M	33.4M
Liabilities And Stockholders Equity	(80.6M)	(153.1M)	(256.2M)	(403.3M)	635.4M	667.1M
Non Current Liabilities Total	4.9M	4.0M	3.1M	8.1M	52.3M	54.9M
Other Current Assets	4.9M	6.6M	912K	8.3M	6.2M	3.9M
Other Stockholder Equity	(210.9M)	(336.5M)	(607.2M)	(755.5M)	(680.0M)	(646.0M)
Total Liab	13.2M	14.5M	19.1M	35.8M	96.2M	101.1M
Property Plant And Equipment Gross	6.5M	3.2M	8.2M	9.1M	62.5M	65.6M
Total Current Assets	123.3M	177.5M	344.7M	345.2M	574.2M	602.9M
Accumulated Other Comprehensive Income	148K	25K	(382K)	(3.9M)	977K	1.0M
Non Current Liabilities Other	202K	4.8M	4.0M	2K	2.3K	2.2K
Common Stock	210.8M	336.5M	607.6M	759.4M	1.2B	1.3B
Property Plant Equipment	6.5M	5.4M	4.7M	5.0M	5.7M	4.2M
Net Invested Capital	117.1M	168.9M	331.9M	316.3M	539.1M	566.1M
Net Working Capital	115.0M	167.0M	328.7M	317.5M	530.2M	556.7M
Short Term Investments	78.1M	77.8M	133.0M	301.8M	503.7M	528.8M
Capital Stock	210.8M	336.5M	607.6M	759.4M	1.2B	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America

When determining whether Crinetics Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Crinetics Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Crinetics Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Crinetics Pharmaceuticals Stock:

How To Invest In Crinetics

Details

Is Crinetics Stock a good investment?

Details

What is Crinetics Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Crinetics Stock analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges

Is Crinetics Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crinetics Pharmaceuticals. If investors know Crinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crinetics Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.72)

Revenue Per Share

0.032

Quarterly Revenue Growth

(0.76)

Return On Assets

(0.24)

Return On Equity

(0.41)

The market value of Crinetics Pharmaceuticals is measured differently than its book value, which is the value of Crinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Crinetics Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Crinetics Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crinetics Pharmaceuticals' market value can be influenced by many factors that don't directly affect Crinetics Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Crinetics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crinetics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crinetics Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Crinetics Net Receivables vs Total Liab Analysis

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Total Liab

Crinetics Pharmaceuticals fundamental ratios Correlations

Crinetics Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Crinetics Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Crinetics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Liabilities	+ 0.99	Total Assets

Retained Earnings	- 0.99	Total Current Liabilities
Cash And Short Term Investments	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Net Tangible Assets
Retained Earnings	- 0.98	Other Current Liab
Retained Earnings	- 0.98	Total Assets
Other Stockholder Equity	- 0.94	Common Stock Shares Outstanding